Incidence of Neuroendocrine Neoplasms Reported in England 2015-2017 Abstract #3046

Introduction: Previously published UK Cancer Registry data showed incidence of Neuroendocrine Neoplasms rising between 2001 and 2015. This was higher than had been thought (Genus et al). We report more recent data with more accurate coding (ICD-O-3).
Aim(s): To analyse National Cancer Registration and Analysis Service (NCRAS) data on Neuroendocrine Neoplasias (NENs) in England including years 2015 – 2017.
Materials and methods: Public Health England data for incidence and prevalence of NEN were analysed from NCRAS. This included a breakdown by age group, site, morphology and grade.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Doctor Benjamin E White

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2005 Incidence and Prevalence of Neuroendocrine Tumors in England
Introduction: Historically the incidence and prevalence of neuroendocrine tumours (NETs) has been difficult to establish. Studies by Ellis et al in 2006 estimated the incidence of gastroenteropancreatic neuroendocrine tumours (GEP NETs) to be 1.3 per 100,000 per year (incidence hereafter given as cases per 100,000). However, the SEER USA data suggests a four-fold higher incidence, and prevalence of 35 per 100,000.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Tracey Genus
#2776 The Effects of Somatostatin Analogues on HbA1c and BMI in the Treatment of Neuroendocrine Tumours
Introduction: Long acting somatostatin analogues (SSA) are the most commonly used drugs in the management of neuroendocrine tumours (NETs) due to their ability to control symptoms and prolong survival. SSAs use is associated with changes in glucose metabolism. However, there is lack of data for such effects in patients with NETs. We evaluated the effects of SSA on BMI and HbA1c in our cohort of patients with NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MBBS Kishen Patel
Authors: Patel K, Nahar A, Elhassan Y, Shah T, ...
#2790 Trends of Incidence and Prognosis of Gastric Neuroendocrine Neoplasms - A Study Based on SEER and Our Multicenter Research
Introduction: The incidence of gastric neuroendocrine neoplasms (GNENs) is increasing but we still lack effective tools for risk stratification so far.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Ping Hu
Authors: Hu P, Bai J, Liu M, Tang Q, ...
#2857 Clinical Epidemiology Study of Rectal Neuroendocrine Neoplasms in China: A National Multicenter 10-Year Retrospective Study
Introduction: Representative data on the rectal neuroendocrine neoplasms in Chinese patients is rare.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: professor Fan Jinhu
Authors: Jinhu F, Yihebali C, Huan Y, Su Z, ...
#2937 Brain Metastasis in Patients with Neuroendocrine Neoplasia of Gastroenteropancreatic Origin: A Single Centre Experience
Introduction: Brain metastasis (BrMet) in patients (pts) with neuroendocrine neoplasia (NEN) of gastroenteropancreatic (GEP) origin is extremely rare. Data on management and outcome are limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Javad Saghebi
Authors: Saghebi J, Hicks R, Michael M, Kong G, ...